As more and more clinical trials during the pandemic have harnessed the power of remote assessments and modifications, the FDA Oncology Center of Excellence and the Office of Oncologic Diseases are now requesting that applicants voluntarily add flags to datasets to discriminate between remote assessments and trial site assessments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,